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ABSTRACT
Background: Current treatment options for stage III non-small cell lung cancer (NSCLC) consist of
different combinations of chemotherapy, surgery, radiotherapy and immunotherapy. Treatment choices are
highly individual decisions, in which adverse events (AEs) are relevant for decision-making. This study
aims to analyse reporting of AEs in prospective stage III NSCLC trials, focussing on trials including
radiotherapy and/or surgery.
Methods: PubMed was searched for prospective studies dealing with stage III NSCLC from January 1987
to April 2019. Meta-analyses were screened as a positive control. Pearson’s Chi-squared test and smooth
kernel distribution were used to estimate distributions. Data was resampled using bootstrapping.
Results: Out of 1193 initially identified studies, 119 met the inclusion criteria. Of these, 31 had a surgical
procedure in any study arm. Grade 3 and 4 AEs were reported in 94.12% and 92.44% of the included
studies, respectively. Reporting of grade 5 AEs was provided in 87.39% of cases. Grade 1 and 2 AEs were
less commonly reported at 53.78% and 63.03%, respectively. One study did not mention any AEs. Of the
31 treatment arms including any form of surgery, AEs were not reported in 10. Overall, 231 different AE
items were reported, only 18 of them were included in at least 20% of the analysed studies.
Conclusion: Overall, AE reporting in stage III NSCLC was inconsistent and inhomogeneous. Studies
including surgical study arms often reported only treatment-related deaths in regards of surgical AEs.
Underreporting of AEs prohibits the extraction of patient-relevant information for decision-making and
represents a suboptimal use of invested resources.
@ERSpublications
Adverse event reporting for stage III NSCLC is inconsistent and inhomogeneous. Surgical
studies tend to underreport lower grade adverse effects. Patient-relevant information for
decision-making is lost and invested resources are used suboptimally. https://bit.ly/3gLNIYy
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Background
Stage III non-small cell lung cancer (NSCLC) is a potentially curable disease and patients may qualify for
several treatment options. This collective of patients shows substantial heterogeneity as patients with
different T and N stages, ranging from T4N0 to T4N3, are grouped into stages III A–C [1]. Depending on
extent of disease, curative or palliative treatments are applicable and should be decided in a
multidisciplinary setting. Over time, guidelines kept adapting to new evidence, forming today’s
recommendations. Treatment typically consists of chemotherapy combined with surgery or radiotherapy
[2–4] and recently immunotherapy has become part of the treatment [5]. A multitude of factors may
influence the availability of treatment options for each individual patient [6] (e.g. is a technique
reimbursed?, Is a technique available?) and various criteria may be used to decide [7] (e.g. patient
preference, laboratory findings). Therefore, treatment selection is a multilayered process, integrating
physician- and patient-specific factors, emotional components and institutional criteria (e.g.
implementation of guidelines).
The main differences between treatment strategies based on radiotherapy or surgery in stage III NSCLC
are not quantitative (i.e. similar survival rates) [8], but rather of a qualitative nature. Patient preferences,
the multidisciplinary setting and the treating physicians’ expertise add to the complex process of
decision-making. A knowledge gap between the physician and the patient needs to be addressed by
nuanced communication. This has a significant impact on patients’ expectation and fears, such as adverse
events (AEs). These factors show why shared decision-making is of central importance to enable the
selection of treatments best aligned with patient preferences. While decision aids can support the patient
decision [9, 10], the question of what the respective risk–benefit ratios are (rate of AEs versus cure rates)
remains difficult to answer.
To the patient, significant logistical differences exist between surgery and radiotherapy, for example,
surgery requiring hospitalisation or radiotherapy requiring daily workday treatments for 6–7 weeks. Next
to these logistical issues, potential AEs are essential to the tumour board’s recommendation as well as the
FIGURE 1 Preferred Reporting
Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow chart
visualising the study selection
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patient’s decision. Information that is provided to patients is typically based on trials’ primary outcomes
(survival or cure rates) or registry data. AEs however, seem to be less the focus of current and past
research. Published reviews also rarely deal with AEs, with only 1 in 15 addressing this issue [11, 12].
With this study, we aim to evaluate the quality of AE reporting in prospective trials for stage III lung
cancer, related to their frequency and grading.
Methods
Search strategy
We performed a PubMed search for this systematic review, to identify trials on stage III NSCLC focussing
on radiotherapy and or surgery (for the detailed search strategy see supplementary appendix A). To
complete the list of publications, the meta-analyses gathered on www.pneumocancero.com were screened
and were used as positive control assessing the completeness of the literature search. The search spanned
from January 1987 until April 2019.
Study selection and inclusion criteria
Abstracts obtained by the PubMed search were screened for prospective studies focussing on stage III
NSCLC, investigating curative radiotherapy or surgical regimens. Upon meeting those terms, the respective
full texts were read. Studies were included for the analysis if radiotherapy (definitive, sequential/concurrent
or trimodal setting) or surgery was part of the treatment. This covers single-arm studies, as well as studies
including radiotherapy alone. Larger studies with several publications using the same collection of patients
or separated toxicity reports were integrated as one publication (data were added to the first publication).
If available, online appendices and supplements were screened for toxicity reports. Stage III needed to be
defined according to the TNM classification, fourth edition or later. If no edition was declared, only
studies starting inclusion after January 1, 1998 (after the appearance of the fifth edition) were included.
Randomisation was not a requirement. Reviews, studies including other stages of NSCLC or published in
other languages than English, German or French, were excluded from this systematic review. The process
of the study selection is represented in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow chart (figure 1) [13].
Categorisation and assessment
To identify differences in the reporting of AEs, the studies were grouped according to predefined
characteristics such as study design, year of publication, sample size, geographical features (Europe, North
America, Asia and global) or funding of the study according to the declared sponsors (divided into
pharmaceutical, public or unknown sponsors). All funding coming from governmental sources,
nongovernmental organisations or universities were considered public. If a corporation granted any
money, the study was attributed to the pharmaceutical group. Individual researchers’ honoraria did not
label a study pharmaceutical.
Grading systems used by the authors were analysed. Textual description of AEs (mild, moderate, severe,
life-threatening and death) were transcribed to grade 1 to 5 respectively, according to the Common
Terminology Criteria for AEs (CTCAE), currently published in its fifth edition by the US National
Institutes of Health [14]. If certain grades were specifically mentioned as not occurring (e.g. no toxic
deaths), the respective grading/item was considered as reported. Patient-reported outcome measures
(PROMs), defined as any questionnaire, where patients assess the toxicities themselves, were analysed. Any
form of structured assessment (e.g. paper forms, electronic or by phone call) was considered a PROM, in
accordance to the overview by CHEN et al. [15]. The usage and frequency of the respective questionnaires
were assessed. Data collection and management was handled using the REDCap electronic data capture
tool [16].
Statistics
Pair-wise random permutation tests were used to estimate the statistical significance of the differences
between each subgroup’s mean number of reported AEs and the mean number of reported AEs of the
remaining studies: The null-hypothesis distribution of mean differences was based on 50 000 permutations
of the (AE number)-subgroup assignments. A one-tailed p-value was calculated as the fraction of
null-hypothesis differences that were equal to or larger than the observed difference of means. The
permutation test results were compared to the results of a nonparametric Mann–Whitney location test.
Wolfram Mathematica was used to perform the statistical analyses. A p-value <0.05 was considered as a
cut-off for statistical significance and p-values <0.01 were considered strongly significant.
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Results
Study characteristics
The PubMed search identified 1193 studies. The meta-analyses from www.pneumocancero.com identified
120 studies, of which only 5 were not already included. A total of 119 met the inclusion criteria for this
analysis (see supplementary appendix D). Of these, 31 involved surgery and 96 were randomised. Of those
that declared the study phase, 39 were phase II and 34 were phase III studies. The oldest included studies
were published in 1992 by BURKES et al. [17] and STRAUSS et al. [18], whereas 50% of the studies were
published after 2009. The number of treated patients ranged from 12 to 709 (median 70), with a total of
222 individual treatment arms. Of these, 18 treatment arms used radiotherapy alone, 153 used
radiochemotherapy (sequential or concomitant) and 23 used a trimodal regimen. There were 28 study
arms that consisted of other treatments (surgery alone, surgery combined with different chemotherapy
regimens, neoadjuvant radiotherapy with surgery or chemotherapy alone).
There were 8 global studies, 13 international studies (but confined to one continent) and 98 were
performed at a national level. A total of 40 studies came from European countries, 30 were from North
America and 41 studies were from Asian countries. Overall, 47 (39.5%) studies did not declare any
funding, a third (40, 33.6%) were sponsored by pharmaceutical companies, while 32 studies (26.9%)
received public funds.
Adverse event reporting
Toxicity report
Out of the 119 analysed trials, only one study did not mention toxicities at all. All other studies reported
toxicities in general, but not for all treatment arms. Looking, for example, at studies with surgical arms,
only 21 out of 31 studies (67.7%) reported surgical toxicities.
We identified 231 unique AE items, divided into two groups: nonsurgical or surgical. Nonsurgical AEs
consisted of 119 items described as acute toxicity, 23 as late toxicity and 19 as acute and 10 as late organ
effects (table 1 and supplementary appendix C). Organ effects were attributed to an organ system but not
further specified. The surgical AE group included 60 items (58 acute and 2 late AEs). Some AEs were
reported regularly, whereas others were mentioned by only a few (supplementary ppendix C). In total only
18 AEs were reported by at least one-fifth of the included studies. Focussing on nonsurgical acute or late
toxicity, there were 25 items particularly associated with radiotherapy (e.g. pneumonitis, fistula or
pulmonary fibrosis). There were 32 items associated with chemotherapy, such as polyneuropathy, febrile
neutropenia or renal failure. AEs not specifically attributable to either of them remained unclassified.
Reporting systems
CTCAE is the most frequently used reporting system for AEs, with 66 studies using one of its versions.
Versions 1 to 4 were used 3, 21, 30 and 5 times, respectively. Seven studies did not state what version was
used. In 20 studies, the toxicity was reported using the World Health Organization’s (WHO) scale. Scales
developed by the Radiation Therapy Oncology Group (RTOG) and Eastern Cooperative Oncology Group
(ECOG) or Japan Clinical Oncology Group (JCOG) were used 25 and three times, respectively. In 17
cases, the authors did not specify which grading system was used.
Late adverse events
A total of 31 studies provided any results of late AEs (26.1%). Definitions of acute and/or late AEs were
provided in 30 studies. In 26 studies, the cut-off for late effects was 90 days (e.g. RTOG) and and in three
studies it was 30 days. The rest did not clarify on what terms an AE was considered as a late AE. The
minimum reported general follow-up was 10 months and the longest expanded to 107 months. Overall, 52
studies did not provide insight on how long patients were reassessed.
TABLE 1 Characteristics of nonsurgical adverse event reporting#
Toxicity items Acute (n=119) Late (n=23) Total (n=142)
Radiotherapy 17 (14.3%) 8 (34.8%) 25 (17.6%)
Chemotherapy 27 (22.7%) 5 (21.7%) 32 (22.5%)
Unclassified 75 (63.0%) 10 (43.5%) 85 (59.9%)
#: subgroups “organ acute” and “organ late” not included.
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Grading
Of the 118 trials reporting AEs, they were graded in 114 trials; 94.12% reported grade 3, 92.44% grade 4
and 87.39% reported treatment-related deaths (grade 5), including the reports mentioning no deaths
(figure 2). Lower grades than 3 were not commonly published. They were reported mostly for nonsurgical
AEs for grade 1 and 2 in 53.78% and 63.03% of cases, respectively. In some cases, authors explicitly stated
that specific side effects did not occur (interpreted as grade 0). This was in accordance with older studies
with CTCAE version 2, when this grade existed or in its adaptation for newer studies. There was a
difference in reporting between surgical and nonsurgical AEs (table 2). A Chi-squared test showed highly
significant differences in AE reporting (p⩽0.001) and AE grading (p⩽0.001) Lower grades were more
frequently reported for nonsurgical AEs. Most studies reported only severe AEs (grade 3–5).
Mortality in surgery
While only 14 studies reported surgery-associated deaths, 10 mentioned a time span or specified when
death occurred. Most frequently, in 8 studies, 30-day mortality was reported. In addition, one added
90-day mortality and two others had 120-day mortality. There have been two more studies describing
deaths “while in hospital” and “6 months and later”.
Patient-reported outcomes
PROMs were reported in 10 studies [19]. The oldest trial including a quality of life questionnaire was
published in 2004. Most frequently used questionnaires were the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30, FACT-L and EORTC QLQ-LC14 (an updated edition of the
original LC13).
Group/category-based results
Based on the permutation tests, we found two subgroup mean differences that were statistically
significantly different (p<0.01): Phase II/III versus remaining studies and privately sponsored studies
versus remaining studies (table 3). Phase II/III studies as well as privately sponsored studies reported a
statistically significant higher average number of AEs than their respective out-of-the-subgroup studies.
The results of the Mann–Whitney tests led to the same conclusions.
The same applies to three other subgroups (2009–2019, North American studies, n<70), with less
significant differences (p<0.05) in average number of AEs. For the other groups we cannot reject the null
hypothesis of equal underlying population distributions.
Overall G0 G1 G2 G3 G4 G5 y/n
Nonsurgical (n=119) 99% 27% 54% 63% 94% 92% 87%
Surgical (n=31) 68% 3% 6% 3% 13% 10% 45% 32%
119 118 27 64 75 112 110 104-
31 21 1 2 1 4 3 14 10
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FIGURE 2 Reporting frequencies. Reporting frequency for each grade, divided into surgical and nonsurgical
adverse events (AEs). “y/n” represents studies reporting occurrence or absence of certain AEs without any
grading.
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Discussion
The vast number of 231 different AEs, with only 18 of them being mentioned in at least a fifth of the
studies, showed a large variety in reporting. Different grading systems for AE reporting exist, with partially
different AE items. They all have five grades in common, which dates back to the grading system originally
introduced by the WHO in 1979 [20]. In 1988 with the first appearance of the CTC-criteria (later CTCAE),
an intergroup consensus on reporting was established, adopting the five grades. The terms “mild”,
“moderate”, “severe” and “life-threatening” were consistently used with grade 1 to 4, therefore the studies
stay comparable regardless of the classification system used. With the second version of the CTCAE, there
was the development of a grading system for chemotherapy and radiotherapy as well. Only with the third
version late effects were implemented, mostly from different sources as the RTOG scale or LENT-SOMA
(which was seldomly used in our collective) [21]. The assessment however, remains physician-dependent and
is therefore subjective and at risk of underreporting and/or misreporting [22]. Due to the nature of certain
AEs, some remain subjective. To account for this, the PRO-CTCAE was introduced, defining categories
amenable for patient-based self-reporting [23]. In conclusion, the CTCAE today offers an abundant
catalogue, and the WHO and different collaboration groups depend on it today. Some authors of newer
papers claiming to have used the WHO scale, without reference, may have therefore used the CTCAE. There
is a high chance of underestimation of the true usage occurred in our review.
Regarding the differentiation between acute and late AEs, the clinically still often used “90-day-rule” was
abandoned in 2006 with the introduction of version 3 of the CTCAE and left to the investigator’s decision [18].
However, our review showed that there is a serious lack of providing a definition as well as reporting of late
effects in general. We assume that in clinical work and therefore in studies, these 90 days still act as a reference
point. Especially surgical studies usually define 30-day and 90-day mortality as common end-points. Several
studies reported doubled mortality rates regardless of the extent of surgical resection, comparing 90-day to
30-day mortality indicating a high impact of timeline definition [24, 25]. In general, longer follow-up should be
preferred; this applies to any treatment modality.
TABLE 2 Comparison of radio(chemo)therapy- versus surgery-associated adverse events (AEs)
Radio(chemo)therapy Surgery
Studies n# 112 31
Reporting AEs 111 (99.1%) 21 (67.7%)
Grading 107 (95.5%) 9 (29.0%)
Only grade 5 reported 2 (1.7%) 3 (9.7%)
AE items in total n 1426 138
Reported acute AE/study 12.73±8.88 (0–65) 4.45±5.98 (0–28)
Data are presented as n (%) or Mean±SD (range), unless otherwise stated #: studies may be counted in
both groups, according to their respective arms (e.g. comparing radiotherapy to surgery).
TABLE 3 Reporting of adverse events (AEs) divided by category
n Mean AE/study p-value only >grade 3 no grading <grade 3
1992–2008 58 10.95±5.87 (0–33) 0.0374 21 3 34
2009–2019 61 13.79±10.67 (0–65) #0.0374 22 2 37
Phase II/III 75 13.80±9.18 (0–65) 0.0084 33 3 39
Not specified trials 44 10.02±7.47# (0–17) #0.0084 10 2 32
AE as secondary end-point 68 11.91±6.99 (0–38) 0.2462 24 3 41
Not a secondary end-point 51 13.06±10.70# (0–65) #0.2462 19 2 30
n<70 59 10.98±5.65 (1–24) 0.0388 12 2 45
n⩾70 60 13.80±10.85 (0–65) 0.0551 31 3 26
Europe 40 11.25±6.42 (0–33) 0.1582 14 2 24
North America 30 15.63±12.24 (0–65) 0.0136 13 2 15
Asia 41 11.00±6.23 (1–25) 0.1016 11 1 29
Global 8 13.25±12.40 (4–40) 0.3411 5 0 3
Private sponsors 40 16.20±11.98 (1–65) 0.0003 17 0 23
Public sponsors 32 10.69±5.95 (0–25) 0.0941 14 2 16
Funding unknown 47 10.34±5.65 (0–23) 0.0153 12 3 32
#: mean values for both subgroups formed show clear dependence due to their underlying distribution.
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In stage III NSCLC, patients may qualify for different treatment options. Depending on initial stage,
resection with neoadjuvant or adjuvant chemotherapy or definitive radiochemotherapy (potentially
followed by immunotherapy) are standards of care [4, 5, 26]. Nodal stage or patients’ morbidity often sets
limitation to resectability, shifting the recommendation to definitive chemoradiotherapy [3]. Providing
prognostic information as well as most important side effects of the different treatments is crucial for a
shared and informed decision. Haematological AEs (all blood cell lines) were most frequently reported
AEs, mainly for chemotherapy. Radiation pneumonitis (66 studies) and oesophagitis (77 studies) were the
most commonly reported as radiotherapy-associated acute AEs. In long-term observation, oesophageal
stenosis, lung fibrosis and pneumonitis were most commonly listed. Surgical studies reported bronchial
obstruction and fistulas (13 studies), empyema (9 studies), pneumonia (10 studies) and respiratory failure
as main AEs (supplementary appendix C). Our study showed a lack of reporting of grade 1 and 2 AEs.
They were reported in 53.78% and 63.03%, respectively of the included studies, mainly for nonsurgical
AEs. Although grade 1 and 2 are seen by physicians as “tolerable” AEs, these side effects may highly
impact the patient’s decision-making process, which was impressively shown by TOL-GEERDINK et al. [27].
Therefore, exact knowledge of side effects of oncological treatment is crucial. In our collective, only 27
studies (22.69%) reported whether patients did not have any AEs (equal to CTCAE “grade 0”).
There was a substantial difference in AE reporting, considering surgery related and nonsurgical AEs.
While surgery-associated AEs, with 60 different items and only 67.7% of the studies reporting any AEs,
perform poorly in our investigation, as many as 22 of them did not grade them properly. Nonsurgical AEs
were more commonly reported with a total of 231 items. Surgical side effects are well known and
especially in lower grades of little interest. Follow-up in surgical studies mostly is too short to report
long-term AEs adequately. For oncological surgery, resection status and survival rates seem to be more of
clinical interest. However, more and more studies appeared focussing on quality of life after surgery,
showing a decline during short- and long-term follow-up [28–30]. Different AEs, such as chronic pain,
anxiety/depression or general mental function are increasingly moving into focus. These AEs are often
measured by using PROMs, which were initially designed for clinical trials. Therefore, it is not a surprise
that these instruments gained in popularity, as the difference of effectiveness in treatments became smaller
and smaller [31]. This interest in the clinical trial setting led to more frequent transfer of PROMs into
daily practice [32, 33]. Different analyses, in trials and daily practice, showed high discrepancies of
physician and patient-reported AEs and their respective severity [34, 35]. This discrepancy and intensified
focus on patient centred care had an impact on trial design [36]. The EORTC initiated a consortium to
provide recommendations on standardisation and analysis of quality of life end-points and other PROMs
in clinical trials [37]. Our analysis shows a slightly higher reported mean of AE per study in newer studies
from 2009 to 2019 (p=0.0374). This could be in correlation with a higher usage of PROMs and therefore,
a larger number of structured AE assessments.
Around a quarter of the examined studies were publicly funded and one-third were privately sponsored.
Another third of the collective did not declare any funds. To maximise the profit of this invested capital,
the maximum of output in clinical research should be defined as goal (this includes an improvement in
the quality of AE reporting). Although there are guidelines in using the CTCAE, no clear definition of
quality of toxicity reporting exists. Besides completeness of toxicity reports, the coherence to the CTCAE
grading and transfer of patients’ information into grade 1 to 5 need to be assessed carefully [22, 38].
During clinical examinations AEs are regularly assessed but not reported in the final publications, resulting
in limited availability of existing data. Ideally, this awareness should be improved among investigators,
sponsors as well as journal editors.
Although we showed important shortcomings of AE reporting, a number of limitations need to be
considered. As in all reviews, selection bias may interfere with our findings. Namely potential selection
bias of trials due to publication bias and search criteria, including language restrictions, may have distorted
our collective of included studies. Some of the data concerning AE reporting were not available, as they
were not published or not presented in their entirety. However, while this review certainly misses data, we
extracted enough information providing a well-based overview. To our knowledge, this is the first detailed
analysis of AE reporting in lung cancer with an extensive inclusion of trials. The findings were not only
restricted to one treatment modality but also present the range of clinically relevant lung cancer
treatments. Our findings were assessed and discussed in a multidisciplinary team, including radiation
oncologists, surgeons and oncologists.
Conclusion
Even though the CTCAE provides an abundant and thorough catalogue of AEs and their clinical grading,
overall reporting of AEs in stage III NSCLC for both radiotherapy/oncology and surgery was inconsistent
and inhomogeneous. As all included studies were interventional, all of them may be expected to report AEs.
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Underreporting of AEs prohibits the extraction of patient-relevant information for decision-making and
represents suboptimal use of invested resources.
Conflict of interest: I. Iseli has nothing to disclose. T. Berghmans has nothing to disclose. M. Glatzer has nothing to
disclose. A. Rittmeyer reports grants from AbbVie, AstraZeneca, BMS, Eli Lilly, Boehringer Ingelheim, MSD, Pfizer and
Roche, outside the submitted work. G. Massard has nothing to disclose. V. Durieux has nothing to disclose.
T. Buchsbaum has nothing to disclose. P.M. Putora has nothing to disclose.
References
1 Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the
TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac
Oncol 2016; 11: 39–51.
2 Evison M, Clive A, Castle L, et al. Resectable clinical N2 non–small cell lung cancer: what is the optimal treatment
strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. J Thorac Oncol 2017;
12: 1434–1441.
3 Evison M, McDonald F, Batchelor T. What is the role of surgery in potentially resectable N2 non-small cell lung
cancer? Thorax 2018; 73: 1105.
4 Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 non-small cell lung cancer:
surgery or radiotherapy? ERJ Open Res 2020; 6: 00159-2019. in press.
5 Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III
NSCLC. N Engl J Med 2018; 379: 2342–2350.
6 Panje CM, Glatzer M, Siren C, et al. Treatment options in oncology. JCO Clin Cancer Inform 2018; 2: 1–10.
7 Glatzer M, Panje CM, Siren C, et al. Decision-making criteria in oncology. Oncology 2020; 98: 370–378.
8 McElnay PJ, Choong A, Jordan E, et al. Outcome of surgery versus radiotherapy after induction treatment in
patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax 2015; 70: 764–768.
9 Ankolekar A, Dekker A, Fijten R, et al. The benefits and challenges of using patient decision aids to support
shared decision making in health care. JCO Clin Cancer Inform 2018; 2: 1–10.
10 McAlpine K, Lewis KB, Trevena LJ, et al. What is the effectiveness of patient decision aids for cancer-related
decisions? A systematic review subanalysis. JCO Clin Cancer Inform 2018; 2: 1–13.
11 Ernst E, Pittler MH. Systematic reviews neglect safety issues. Arch Intern Med 2001; 161: 125–126.
12 Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: survey
results. J Clin Epidemiol 2008; 61: 597–602.
13 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. BMJ 2009; 339: b2535.
14 US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE)
version 4.0. Bethesda, National Cancer Institute. 2009.
15 Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient-reported outcome
measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13:
211.
16 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) - A metadata-driven
methodology and workflow process for providing translational research informatics support. J Biomed Inform
2009; 42: 377–381.
17 Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for
stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10:
580–586.
18 Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in
stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin
Oncol 1992; 10: 1237–1244.
19 Giordano FA, Welzel G, Siefert V, et al. Digital follow-up and the perspective of patient-centered care in oncology:
what’s the PROblem? Oncology 2020; 98: 379–385.
20 Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
21 Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181.
22 Zhang S, Liang F, Tannock I. Use and misuse of common terminology criteria for adverse events in cancer clinical
trials. BMC Cancer 2016; 16: 392.
23 Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes
version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106:
dju244.
24 Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double
30-day mortality. J Thorac Cardiovasc Surg 2014; 148: 2269–2278.
25 Green A, Hauge J, Iachina M, et al. The mortality after surgery in primary lung cancer: results from the Danish
Lung Cancer Registry. Eur J Cardiothorac Surg 2016; 49: 589–594.
26 Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in
locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181–2190.
27 van Tol-Geerdink JJ, Stalmeier PFM, Pasker-de Jong PCM, et al. Systematic review of the effect of radiation dose
on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys
2006; 64: 534–543.
28 Rauma V, Sintonen H, Räsänen JV, et al. Long-term lung cancer survivors have permanently decreased quality of
life after surgery. Clin Lung Cancer 2015; 16: 40–45.
29 Hopkins KG, Ferson PF, Shende MR, et al. Prospective study of quality of life after lung cancer resection.
Ann Transl Med 2017; 5: 204.
https://doi.org/10.1183/23120541.00010-2020 8
LUNG CANCER | T. ISELI ET AL.
30 Ayabe T, Tomita M, Nose N, et al. Patient-reported outcomes of surgery of non-small cell lung cancer: evaluation
based on the questionnaires of anti-aging quality of life and the European Organization for the Research and
Treatment of Cancer quality of life questionnaire. Surg Sci 2017; 8: 203.
31 Bouazza YB, Chiairi I, El Kharbouchi O, et al. Patient-reported outcome measures (PROMs) in the management
of lung cancer: a systematic review. Lung Cancer 2017; 113: 140–151.
32 Fleischmann M, Vaughan B. The challenges and opportunities of using patient reported outcome measures
(PROMs) in clinical practice. Int J Osteopath Med 2018; 28: 56–61.
33 Weenink J-W, Braspenning J, Wensing M. Patient reported outcome measures (PROMs) in primary care:
an observational pilot study of seven generic instruments. BMC Fam Pract 2014; 15: 88.
34 Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects
associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg 2016; 142:
517–523.
35 Holmes MM, Lewith G, Newell D, et al. The impact of patient-reported outcome measures in clinical practice for
pain: a systematic review. Qual Life Res 2017; 26: 245–257.
36 Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or
tumour-centred end-point? Eur J Cancer 2009; 45: 2249–2252.
37 Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for
cancer clinical trials: a start in setting international standards. Lancet Oncol 2016; 17: e510–e514.
38 Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in
oncology. J Clin Oncol 2007; 25: 5121–5127.
https://doi.org/10.1183/23120541.00010-2020 9
LUNG CANCER | T. ISELI ET AL.
